EmTechMIT, Cambridge, MA: In recent years, enterprise R&D in biotechnology has been fundamentally reshaped by the rise of artificial intelligence. At EmTechMIT, Chief Business & Legal Officer Sarah Korman of Isomorphic Labs (ISO), the Alphabet-backed spinout from Google’s DeepMind, offered a behind-the-scenes look at how AI is accelerating the design and development of novel medicines…